An official website of the United States government
Here's how you know
Official websites use .gov
A
.gov website belongs to an official
government organization in the United States.
Secure .gov websites use HTTPS
A lock (
) or https:// means you've safely
connected to the .gov website. Share sensitive
information only on official, secure websites.
As a library, NLM provides access to scientific literature. Inclusion in an NLM database does not imply endorsement of, or agreement with,
the contents by NLM or the National Institutes of Health.
Learn more:
PMC Disclaimer
|
PMC Copyright Notice
1Division of Pulmonary and Critical Care Medicine, University of Michigan Health System, Ann Arbor, MI, USA, wlabaki@med.umich.edu
✉
Correspondence: Wassim W Labaki, Division of Pulmonary and Critical Care Medicine, University of Michigan Health System, 3916 Taubman Center, 1500 East Medical Center Drive, Ann Arbor, MI 48109, USA, Email wlabaki@med.umich.edu
The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed.
In a recent issue of the International Journal of Chronic Obstructive Pulmonary Disease, Kawamatawong et al reported an association between chest CT-detected bronchiectasis and frequent or severe respiratory exacerbations in 72 Thai patients with COPD (adjusted odds ratio [OR] 4.99; 95% CI 1.31–18.94; p=0.018).1 Frequent exacerbations were defined as two or more events per year, and severe ones as those requiring hospitalization. The results of this study are consistent with those previously reported by Martínez-García et al who found bronchiectasis to be independently associated with severe COPD exacerbations in 92 subjects (OR 3.07; 95% CI 1.07–8.77; p=0.037).2
While the prevalence of bronchiectasis in individuals with COPD varies depending on the selected cohort, it is increasingly recognized as a major contributor to COPD morbidity and mortality.3 This contribution is better understood by assessing epidemiological measures of impact such as the population-attributable risk percent (PAR%) and the attributable risk percent (AR%).4 The PAR% calculated based on Table 1, which was constructed using data from the study by Kawamatawong et al, is 28.3%. If we assume a causal relationship between the presence of bronchiectasis and respiratory exacerbations, this would mean that 28.3% of respiratory exacerbations in this entire COPD cohort can be attributed to bronchiectasis. The calculated AR% is 45.4%, meaning that 45.4% of respiratory exacerbations in COPD patients with bronchiectasis can be attributed to their bronchiectasis.
Table 1.
Number of severe/frequent COPD exacerbations in patients with and without bronchiectasis
These PAR% and AR% measures suggest a relatively high impact of bronchiectasis on the frequency and severity of respiratory exacerbations in COPD. Similarly, severe and recurrent exacerbations may also themselves contribute to the incidence or worsening of bronchiectasis. However, clinical data on patients with coexisting COPD and bronchiectasis are scarce as obtaining a chest CT is not currently part of routine care for COPD. In addition, the role of targeted bronchiectasis therapy (such as inhaled antibiotics, prolonged intravenous antibiotics, mucolytic agents and high-frequency chest wall oscillation) in this COPD/bronchiectasis overlap phenotype still needs to be determined.5 These knowledge gaps emphasize the importance of enrolling such patients into dedicated clinical trials to identify best management practices and improve outcomes.
Acknowledgments
This communication was supported by the US National Institutes of Health grant K24 HL138188.
Footnotes
Disclosure
MKH reports consulting for Boehringer Ingelheim, GlaxoSmithKline and AstraZeneca, and research support from Novartis and Sunovion. WWL reports no conflicts of interest in this work.
References
1.Kawamatawong T, Onnipa J, Suwatanapongched T. Relationship between the presence of bronchiectasis and acute exacerbation in Thai COPD patients. Int J Chron Obstruct Pulmon Dis. 2018;13:761–769. doi: 10.2147/COPD.S139776. [DOI] [PMC free article] [PubMed] [Google Scholar]
2.Martínez-García MÁ, Soler-Cataluña JJ, Donat Sanz Y, et al. Factors associated with bronchiectasis in patients with COPD. Chest. 2011;140(5):1130–1137. doi: 10.1378/chest.10-1758. [DOI] [PubMed] [Google Scholar]
3.Martinez-García MA, de la Rosa Carrillo D, Soler-Cataluña JJ, et al. Prognostic value of bronchiectasis in patients with moderate-to-severe chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2013;187(8):823–831. doi: 10.1164/rccm.201208-1518OC. [DOI] [PubMed] [Google Scholar]
4.Kleinbaum DG, Kupper LL, Morgenstern H. Epidemiologic Research: Principles and Quantitative Methods. Belmont, CA: Lifetime Learning Publications; 1982. [Google Scholar]
5.O’Donnell AE. Bronchiectasis in patients with COPD: a distinct COPD phenotype? Chest. 2011;140(5):1107–1108. doi: 10.1378/chest.11-1484. [DOI] [PubMed] [Google Scholar]
Int J Chron Obstruct Pulmon Dis. 2018 Jul 31;13:2337–2338.
The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed.
We thank Labaki and Han for their comments on our recent study. Calculation of frequent exacerbation risk of the entire COPD cohort was shown in the contingency table. The increased frequency of exacerbation in patients with CT-detected bronchiectasis compared to those with COPD without bronchiectasis was noted. Hence, population-attributable risk percent and attributable risk percent for COPD exacerbation were 28.3% and 45.4%, respectively. This finding emphasizes the risk of poor COPD outcome in the presence of bronchiectasis. A previous report by Hurst et al showed that both the frequency of exacerbation and hospitalized exacerbation were increased in the presence of bronchiectasis, according to Global Initiative for Chronic Obstructive Lung Disease (GOLD) stages.1 Likewise, severe airflow limitation (forced expiratory volume in one second [FEV1] <50%) was associated with frequent exacerbation (p=0.002) in the study by Kawamatawong et al.2 Despite that bronchiectasis is independently associated with frequent COPD exacerbation, the difference in lung function impairment between COPD patients with and without bronchiectasis was not detected. According to the study by Martínez-García et al, the prevalence of bronchiectasis was high among those with severe COPD compared to those with moderate disease (p=0.001). In addition, hospitalized exacerbation was independently associated with bronchiectasis.3 Bronchiectasis worsened by COPD exacerbation is associated with aging, pathogenic bacterial airway colonization and severe systemic inflammation.4 Both COPD and bronchiectasis are considered different disease entities but can coexist.5 Effective treatment for coexisting bronchiectasis and COPD has never been studied. The treatments of adults with bronchiectasis including long-term macrolide and aerosolized antibiotics and airway clearance have been addressed.6 Macrolide therapy has been shown to effectively prevent COPD exacerbation.7 Hence, it has been recommended for high-risk and symptomatic COPD. However, occult mycobacterial infection and macrolide-resistant pathogens have been reported. The prevalence of mycobacterial infection among COPD patients in our cohort and another study was low.8 Mycobacterium screening prior to starting macrolide is not routine. N-acetyl cysteine has been investigated in COPD.9 Studies examining the efficacy of N-acetyl cysteine on COPD with bronchiectasis are limited. In addition, roflumilast has been shown to be effective in severe COPD associated with frequent exacerbations and chronic bronchitis.10 Evidence demonstrating the efficacy of roflumilast on bronchiectasis is limited.11
In summary, the CT-detected bronchiectasis is associated with frequent COPD exacerbations. The potential mechanistic links and causality have to be further elucidated. Lastly, effective treatments for bronchiectasis coexisting with COPD are urgently required.
Footnotes
Disclosure
The authors report no conflicts of interest in this communication.
References
1.Hurst JR, Vestbo J, Anzueto A, et al. Evaluation of COPD Longitudinally to Identify Predictive Surrogate Endpoints (ECLIPSE) Investigators Susceptibility to exacerbation in chronic obstructive pulmonary disease. N Engl J Med. 2010;363(12):1128–1138. doi: 10.1056/NEJMoa0909883. [DOI] [PubMed] [Google Scholar]
2.Kawamatawong T, Onnipa J, Suwatanapongched T. Relationship between the presence of bronchiectasis and acute exacerbation in Thai COPD patients. Int J Chron Obstruct Pulmon Dis. 2018;13:761–769. doi: 10.2147/COPD.S139776. [DOI] [PMC free article] [PubMed] [Google Scholar]
3.Martínez-García MA, Soler-Cataluña JJ, Donat Sanz Y, et al. Factors associated with bronchiectasis in patients with COPD. Chest. 2011;140(5):1130–1137. doi: 10.1378/chest.10-1758. [DOI] [PubMed] [Google Scholar]
4.Ni Y, Shi G, Yu Y, Hao J, Chen T, Song H. Clinical characteristics of patients with chronic obstructive pulmonary disease with comorbid bronchiectasis: a systemic review and meta-analysis. Int J Chron Obstruct Pulmon Dis. 2015;10:1465–1475. doi: 10.2147/COPD.S83910. [DOI] [PMC free article] [PubMed] [Google Scholar]
6.Chalmers JD, Aliberti S, Blasi F. Management of bronchiectasis in adults. Eur Respir J. 2015;45(5):1446–1462. doi: 10.1183/09031936.00119114. [DOI] [PubMed] [Google Scholar]
7.Albert RK, Connett J, Bailey WC, et al. COPD Clinical Research Network Azithromycin for prevention of exacerbations of COPD. N Engl J Med. 2011;365(8):689–698. doi: 10.1056/NEJMoa1104623. [DOI] [PMC free article] [PubMed] [Google Scholar]
8.Palwatwichai A, Chaoprasong C, Vattanathum A, Wongsa A, Jatakanon A. Clinical, laboratory findings and microbiologic characterization of bronchiectasis in Thai patients. Respirology. 2002;7(1):63–66. doi: 10.1046/j.1440-1843.2002.00367.x. [DOI] [PubMed] [Google Scholar]
9.Decramer M, Rutten-van Mölken M, Dekhuijzen PN, et al. Effects of N-acetylcysteine on outcomes in chronic obstructive pulmonary disease (Bronchitis Randomized on NAC Cost-Utility Study, BRONCUS): a randomised placebo-controlled trial. Lancet. 2005;365(9470):1552–1560. doi: 10.1016/S0140-6736(05)66456-2. [DOI] [PubMed] [Google Scholar]
10.Rennard SI, Calverley PM, Goehring UM, Bredenbroker D, Martinez FJ. Reduction of exacerbations by the PDE4 inhibitor roflumilast – the importance of defining different subsets of patients with COPD. Respir Res. 2011;12:18. doi: 10.1186/1465-9921-12-18. [DOI] [PMC free article] [PubMed] [Google Scholar]
11.Kawamatawong T. Roles of roflumilast, a selective phosphodiesterase 4 inhibitor, in airway diseases. J Thorac Dis. 2017;9(4):1144–1154. doi: 10.21037/jtd.2017.03.116. [DOI] [PMC free article] [PubMed] [Google Scholar]
